Epigenetic Therapies in Acute Myeloid Leukemia: Role of Agents & Combinations

0
0
0

Epigenetic Therapies in Acute Myeloid Leukemia: The Role of Hypomethylating Agents, Histone Deacetylase Inhibitors, and Combination Regimens

Acute myeloid leukemia (AML) is a hematologic malignancy characterized by genetic and epigenetic heterogeneity. Despite advances in understanding leukemogenesis, treatment outcomes, particularly in older patients and those with high-risk features, remain suboptimal. Intensive chemotherapy (IC), often combined with hematopoietic stem cell transplantation (HSCT), remains the standard for fit patients. However, elderly patients or those with comorbidities frequently cannot tolerate such regimens, leading to poor survival rates. Epigenetic dysregulation, including aberrant DNA methylation and histone modifications, is a hallmark of AML pathogenesis. This has spurred the development of epigenetic therapies, primarily hypomethylating agents (HMAs) and histone deacetylase (HDAC) inhibitors, which aim to reverse these abnormalities. While these agents show promise, their mechanisms, therapeutic effects, and optimal use—either alone or in combination—require further exploration.

Hypomethylating Agents (HMAs) in AML

Mechanisms of Action

HMAs, such as decitabine (DAC) and 5-azacytidine (5-AZA), inhibit DNA methyltransferases (DNMTs), enzymes responsible for adding methyl groups to DNA. By incorporating into DNA or RNA, these agents deplete DNMTs, leading to DNA hypomethylation and reactivation of silenced tumor suppressor genes. At low doses, HMAs primarily exert epigenetic effects, while higher doses cause cytotoxicity by disrupting DNA synthesis. DAC, a DNA-specific DNMT inhibitor, induces more pronounced demethylation than 5-AZA, which also incorporates into RNA, affecting protein synthesis. Preclinical studies suggest HMAs sensitize leukemic cells to chemotherapy by promoting cell cycle entry and upregulating pro-apoptotic genes.

Clinical Trials of HMAs

  1. Monotherapy in Older/Unfit Patients

    • Decitabine: A phase III trial (DACO-016) compared DAC (20 mg/m²/day for 5 days) to low-dose cytarabine (LDAC) or supportive care in older AML patients. DAC showed a higher overall response rate (ORR: 18% vs. 8%) and a trend toward improved median overall survival (OS: 8 vs. 5 months). Subgroup analysis revealed better outcomes in patients with 30% bone marrow blasts (median OS: 8.6 vs. 4.7 months).
    • 5-Azacytidine: The AZA-001 trial demonstrated superior OS with 5-AZA (24.5 months) compared to conventional care regimens (CCR) in AML patients with 20%–30% blasts. A subsequent phase III trial (AML-001) in patients with ≥30% blasts showed similar complete remission (CR) rates between 5-AZA (28%) and CCR (25%), but improved OS in censored analysis (12.1 vs. 6.9 months).

  2. Combination with Chemotherapy
    Sequential regimens of HMAs followed by IC (eg, cytarabine + anthracycline) have shown synergy. A phase I study priming with DAC before IC achieved a 90% ORR (57% CR) in older AML patients. However, a phase II trial combining 5-AZA with IC failed to improve survival over IC alone, highlighting the need for patient stratification based on cytogenetic risk and molecular markers.

  3. Predictors of Response
    TP53 mutations and adverse-risk cytogenetics correlate with higher HMA response rates. For instance, patients with TP53 mutations treated with DAC achieved 100% CR compared to 41% in wild-type cases. However, OS remained comparable, underscoring the complexity of resistance mechanisms.

HDAC Inhibitors in AML

Mechanisms of Action

HDAC inhibitors (eg, vorinostat, panobinostat, valproic acid [VPA]) block deacetylation of histones, leading to chromatin relaxation and reactivation of genes involved in differentiation, apoptosis, and cell cycle arrest. These agents also modulate non-histone proteins, such as transcription factors and chaperones. For example, panobinostat degrades the AML1/ETO oncoprotein in t(8;21) AML, while VPA enhances natural killer (NK) cell-mediated cytotoxicity by upregulating NK ligands on leukemic cells.

Clinical Trials of HDAC Inhibitors

  1. Monotherapy
    HDAC inhibitors alone show limited efficacy. A phase II trial of vorinostat in relapsed/refractory (r/r) AML reported a 4.5% CR rate, while VPA combined with all-trans retinoic acid (ATRA) achieved a 24% response rate in MDS and AML patients.

  2. Combination with Chemotherapy

    • Vorinostat: In a phase II trial, vorinostat added to idarubicin + cytarabine improved ORR to 85%, with FLT3-ITD-mutated patients achieving 100% response. A phase III trial (SWOG 1203) showed similar CR rates across vorinostat + IC and IC-alone arms, but favorable-risk patients had better outcomes with IC alone.
    • Panobinostat: Combined with idarubicin + cytarabine, panobinostat achieved a 64% CR rate in elderly AML patients. A phase I trial in high-risk AML reported a 60.9% ORR, with 43.5% CR and 17.4% CR with incomplete recovery (CRi).

  3. Maintenance Post-Transplant
    Panobinostat maintenance after allogeneic HSCT in high-risk AML/MDS patients resulted in a 20% relapse rate and 75% 2-year relapse-free survival (RFS), suggesting a role in preventing relapse.

Combination of HMAs and HDAC Inhibitors

Preclinical Rationale

Synergy between HMAs and HDAC inhibitors arises from sequential epigenetic modulation: HMAs demethylate DNA, while HDAC inhibitors enhance chromatin accessibility. Preclinical studies demonstrate co-treatment upregulates tumor suppressors (eg, p21) and downregulates oncogenes (eg, MYC). For example, DAC + panobinostat induced genome-wide expression changes in AML cells, while chidamide + DAC blocked cell cycle progression and promoted apoptosis.

Clinical Trials

  1. 5-AZA + HDAC Inhibitors

    • A phase II trial compared 5-AZA ± vorinostat in AML/MDS. No significant differences in ORR (41% vs. 42%) or OS (median: 9.6 vs. 11.0 months) were observed.
    • The phase II/III NORTH trial evaluated 5-AZA ± entinostat in MDS/AML. Hematologic normalization rates were similar (32% vs. 27%), but OS trended shorter in the combination arm (13 vs. 18 months).

  2. Novel Combinations

    • Pracinostat + 5-AZA: A phase II trial in older AML patients reported a 52% response rate (42% CR, 6% morphologic leukemia-free state) and median OS of 19.1 months, suggesting improved efficacy over 5-AZA alone.
    • CDCAG Regimen: Chidamide + DAC + chemotherapy (aclarubicin + cytarabine + G-CSF) in r/r AML yielded a 46% ORR, with TP53-mutated patients showing higher response rates (55.6%).

  3. Challenges
    Heterogeneous trial outcomes highlight issues with dosing schedules, toxicity, and patient selection. For instance, HDAC inhibitors like vorinostat may antagonize HMA effects by reducing demethylation. Optimizing drug sequences (eg, HMA priming followed by HDAC inhibition) and identifying predictive biomarkers (eg, NPM1 mutations) are critical.

Future Directions and Challenges

  1. Biomarker-Driven Therapy
    Molecular profiling (eg, TP53, FLT3-ITD, DNMT3A) may identify patients likely to benefit from epigenetic therapies. For example, TP53-mutated AML shows high HMA sensitivity but poor long-term outcomes, necessitating combo regimens.

  2. Triple Combinations
    Preclinical data support adding AXL or BCL-2 inhibitors (eg, venetoclax) to HMA + HDAC inhibitor regimens. Early trials of HMAs + venetoclax show promise, with CR rates up to 67% in older AML patients.

  3. Optimizing Schedules
    Prolonged low-dose HMA regimens (eg, 10-day DAC cycles) may enhance efficacy. A phase II study using 10-day DAC achieved a 64% ORR in adverse-risk AML, supporting further evaluation.

  4. Epigenetic Priming
    Priming with HMAs before IC or targeted therapy (eg, FLT3 inhibitors) may overcome resistance. A phase I trial priming DAC before cytarabine + anthracycline achieved 90% ORR, warranting randomized studies.

  5. Toxicity Management
    HDAC inhibitors often cause cytopenias and gastrointestinal toxicity. Prophylactic strategies (eg, G-CSF support) and dose adjustments (eg, reduced panobinostat doses) are essential for tolerability.

Conclusion

Epigenetic therapies represent a paradigm shift in AML treatment, particularly for older and high-risk patients. HMAs like DAC and 5-AZA have established roles, while HDAC inhibitors show potential in combination regimens. Despite mixed clinical trial results, advances in understanding molecular mechanisms, drug sequencing, and biomarker selection offer hope for personalized approaches. Future research must address resistance mechanisms, optimize combinatorial strategies, and integrate epigenetic therapies with emerging targeted agents to improve long-term outcomes in AML.

DOI: https://doi.org/10.1097/CM9.0000000000000685

Was this helpful?

0 / 0